News
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...
Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects a recovery of Wegovy weight-loss drug ...
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Novo Nordisk A/S shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later ...
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) ...
Novo Nordisk (NVO) stock rises after Q1 2025 results, even after the company cut its outlook as it sees a sales recovery for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results